Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques.

Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques.
复制标题

模型解释了Remdesivir治疗的恒河猴中SARS-CoV-2鼻脱落相对于肺脱落的延长。

DOI:
10.1016/j.isci.2022.104448
复制
发表时间:
2022-06-17
期刊:
影响因子:
5.8
通讯作者:
Schiffer, Joshua T.
Schiffer, Joshua T.
中科院分区:
综合性期刊2区
文献类型:
--
作者:
Goyal, Ashish;Duke, Elizabeth R.;Cardozo-Ojeda, E. Fabian;Schiffer, Joshua T.

文献摘要

参考文献

被引文献

相似文献

在临床试验中,瑞德西韦可缩短 SARS-CoV-2 住院患者的康复时间,并在感染早期给予瑞德西韦以防止住院,尽管瑞德西韦并未降低鼻腔病毒载量。在恒河猴中,早期瑞德西韦可以预防肺炎并降低肺部病毒载量,但五天后鼻道中的病毒载量增加。我们开发了数学模型来解释这些结果。我们的模型提出了以下假设:1)与鼻道相比,治疗期间肺部病毒载量单调减少,因为感染依赖性难治性细胞的产生,2)使用不完善的药物轻微减少肺部病毒载量可能会导致肺损伤大幅减少,3)鼻腔病毒载量可能会增加,因为峰值病毒载量减弱,从而降低了先天免疫反应的强度。我们证明,效力更高的药物可以降低鼻道和肺部的病毒载量。数学模型捕获了瑞德西韦治疗期间肺部病毒载量的减少 该模型预测了足以限制肺部损伤的中等抗病毒效力 肺部难治性细胞的产生可能有助于限制肺部损伤 该模型解释了治疗期间鼻腔病毒载量的惊人增加 分子模型;病毒学
In clinical trials, remdesivir decreased recovery time in hospitalized patients with SARS- CoV-2 and prevented hospitalization when given early during infection, despite not reducing nasal viral loads. In rhesus macaques, early remdesivir prevented pneumonia and lowered lung viral loads, but viral loads increased in nasal passages after five days. We developed mathematical models to explain these results. Our model raises the following hypotheses: 1) in contrast to nasal passages, viral load monotonically decreases in lungs during therapy because of infection-dependent generation of refractory cells, 2) slight reduction in lung viral loads with an imperfect agent may result in a substantial decrease in lung damage, and 3) increases in nasal viral load may occur because of a blunting of peak viral load that decreases the intensity of the innate immune response. We demonstrate that a higher potency drug could lower viral loads in nasal passages and lungs. A math model captures viral load decrease in lungs during remdesivir treatment The model predicts moderate antiviral potency sufficient to limit lung damage Generation of refractory cells in lung may assist in limiting lung damage The model explains the surprising increase in nasal viral load during treatment Molecular modeling; Virology
DOI: 10.3390/v9110350
发表时间: 2017-11-18
期刊: Viruses
影响因子: --
作者:
Goyal A;Ribeiro RM;Perelson AS
通讯作者: Perelson AS
DOI: 10.1038/s41385-018-0096-2
发表时间: 2019-01
期刊: Mucosal immunology
影响因子: 8
作者:
Hung LY;Sen D;Oniskey TK;Katzen J;Cohen NA;Vaughan AE;Nieves W;Urisman A;Beers MF;Krummel MF;Herbert DR
通讯作者: Herbert DR
DOI: 10.1056/nejmoa2102685
发表时间: 2021-10-07
期刊: The New England journal of medicine
影响因子: --
作者:
Dougan M;Nirula A;Azizad M;Mocherla B;Gottlieb RL;Chen P;Hebert C;Perry R;Boscia J;Heller B;Morris J;Crystal C;Igbinadolor A;Huhn G;Cardona J;Shawa I;Kumar P;Adams AC;Van Naarden J;Custer KL;Durante M;Oakley G;Schade AE;Holzer TR;Ebert PJ;Higgs RE;Kallewaard NL;Sabo J;Patel DR;Dabora MC;Klekotka P;Shen L;Skovronsky DM;BLAZE-1 Investigators
通讯作者: BLAZE-1 Investigators
抗病毒疗法的效力和时机是SARS-COV-2脱落持续时间的决定因素和炎症反应的强度。
DOI: 10.1126/sciadv.abc7112
发表时间: 2020-11
期刊: Science advances
影响因子: 13.6
作者:
Goyal A;Cardozo-Ojeda EF;Schiffer JT
通讯作者: Schiffer JT
一种用于比较主机内SARS-COV-2,MERS-COV和SARS-COV动力学的定量模型提供了有关SARS-COV-2的发病机理和治疗的见解。
DOI: 10.1371/journal.pbio.3001128
发表时间: 2021-03
期刊: PLoS biology
影响因子: 9.8
作者:
Kim KS;Ejima K;Iwanami S;Fujita Y;Ohashi H;Koizumi Y;Asai Y;Nakaoka S;Watashi K;Aihara K;Thompson RN;Ke R;Perelson AS;Iwami S
通讯作者: Iwami S